The role of the serotonin transporter in citalopram pharmacological MRI

The role of the serotonin transporter in citalopram pharmacological MRI - SERT-phMRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42073

Enrollment

Registered

2014-10-27

Start date

2014-12-05

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

serotonine systeem NA

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Three groups of N = 15 each: healthy female volunteers, aged between 18 and 30 without any harddrug exposure including MDMA.

Exclusion criteria

Exclusion criteria: Serious general medical condition or one that could interfere in the interpretation of results, use of (5-HT) medication or supplements and / or illicit (hard) drug use within the last 2 weeks, excessive consumption of alcohol (>21 units/ week), caffeine (greater than eight cups of coffee per day) or cigarette (greater than 15 cigarettes per day), allergy to iodine tablets, contraindications for MRI (e.g. ferromagnetic osteosynthetic material, pacemaker, artificial cardiac valves, claustrophobia), abnormal ECG, or pregnant (a pregnancy test will be administered every visit).

Design outcomes

Primary

Measure	Time frame
1. Change score in thalamic [123I]FP-CIT binding ratio between SPECT scan 1 and 2 (i.e. SERT occupancy), and the interaction effect with citalopram dose. 2. Change score in thalamic CBF (phMRI study). This is the difference between baseline CBF and post-citalopram CBF scores. The interaction effect of delta CBF scores and citalopram dose will also be assessed. Endpoint: association between SERT occupancy and delta CBF.	—

Measure

Time frame

1. Change score in thalamic [123I]FP-CIT binding ratio between SPECT scan 1 and 2 (i.e. SERT occupancy), and the interaction effect with citalopram dose. 2. Change score in thalamic CBF (phMRI study). This is the difference between baseline CBF and post-citalopram CBF scores. The interaction effect of delta CBF scores and citalopram dose will also be assessed. Endpoint: association between SERT occupancy and delta CBF.

—

Countries

Netherlands

Outcome results